1031413-61-2 Usage
Uses
Used in Pharmaceutical Industry:
Spiro[2H-1-benzopyran-2,4'-piperidin]-4(3H)-one, 1'-(1H-indazol-7-ylcarbonyl)-6-Methylis used as a potential drug scaffold for the development of new pharmaceuticals due to its distinctive molecular structure and functional groups. Spiro[2H-1-benzopyran-2,4'-piperidin]-4(3H)-one, 1'-(1H-indazol-7-ylcarbonyl)-6-Methyl-'s ability to be modified and its potential to interact with various biological targets make it a valuable candidate for creating novel therapeutic agents.
The specific applications and reasons for using Spiro[2H-1-benzopyran-2,4'-piperidin]-4(3H)-one, 1'-(1H-indazol-7-ylcarbonyl)-6-Methylin the pharmaceutical industry may include, but are not limited to:
1. As a starting point for the synthesis of new drugs with specific therapeutic targets, given its unique spiro ring system and functional groups that can be further modified to enhance binding affinity and selectivity.
2. For the development of compounds with potential applications in treating various diseases, such as neurological disorders, inflammatory conditions, or cancer, based on the compound's ability to modulate specific biological pathways.
3. In drug discovery research to explore the compound's pharmacological properties and evaluate its potential as a lead compound for further optimization and development into a marketable drug.
Check Digit Verification of cas no
The CAS Registry Mumber 1031413-61-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,1,4,1 and 3 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1031413-61:
(9*1)+(8*0)+(7*3)+(6*1)+(5*4)+(4*1)+(3*3)+(2*6)+(1*1)=82
82 % 10 = 2
So 1031413-61-2 is a valid CAS Registry Number.
1031413-61-2Relevant academic research and scientific papers
Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2
Corbett, Jeffrey W.,Freeman-Cook, Kevin D.,Elliott, Richard,Vajdos, Felix,Rajamohan, Francis,Kohls, Darcy,Marr, Eric,Zhang, Hailong,Tong, Liang,Tu, Meihua,Murdande, Sharad,Doran, Shawn D.,Houser, Janet A.,Song, Wei,Jones, Christopher J.,Coffey, Steven B.,Buzon, Leanne,Minich, Martha L.,Dirico, Kenneth J.,Tapley, Susan,Kirk McPherson,Sugarman, Eliot,James Harwood Jr.,Esler, William
scheme or table, p. 2383 - 2388 (2010/08/03)
Screening Pfizer's compound library resulted in the identification of weak acetyl-CoA carboxylase inhibitors, from which were obtained rACC1 CT-domain co-crystal structures. Utilizing HTS hits and structure-based drug discovery, a more rigid inhibitor was designed and led to the discovery of sub-micromolar, spirochromanone non-specific ACC inhibitors. Low nanomolar, non-specific ACC-isozyme inhibitors that exhibited good rat pharmacokinetics were obtained from this chemotype.
SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS
-
Page/Page column 54; 55, (2008/12/06)
The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.
